CDTHealthcare · Biotechnology

CDT Stock Forecast: CDT Equity, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$2.86

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 21 Aug 2026 — in the weakest quartile.

Market cap

$2.3M

Ticker Nerd rank

15 / 100

Median analyst target

—

Analysts covering

—

Ticker Nerd rank

CDT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CDT Equity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026

15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Growth

Quality

Issuance

Revisions

Momentum

Volatility

Value

Size (99): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CDT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CDT, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CDT appears on the weeks it earns a place.

Estimates

CDT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

CDT Equity, Inc. (CDT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 421.3×
Price / sales: —
Price / book: 0.0×
EV / EBITDA: −0.1×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −69.7%
Return on assets: −23.4%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CDT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
CDTCDT Equity, Inc.	$2.3M	15
OGENOragenics, Inc.	$2.3M	10
SLXNSilexion Therapeutics Corp.	$2.2M	53
DCOYDecoy Therapeutics, Inc.	$2.1M	12
VRAXVirax Biolabs Group Ltd.	$2.5M	13
ONCOOnconetix, Inc.	$2.6M	14
CMNDClearmind Medicine, Inc.	$2.6M	8

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CDT Equity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CDT news & analysis

CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion

GlobeNewsWire · 3 Aug 2026positive

CDT Equity Inc. announced it entered into a strategic transaction to increase its equity stake in Sarborg Limited, an agentic AI intelligence business, to 22.7%. The stake increase is to be funded through the issuance of pre-funded warrants for up to 12,131,770 shares of CDT common stock, subject to shareholder approval at the company's annual meeting on August 28, 2026.

Why it matters — A CDT watcher would care because this deepens CDT's exposure to Sarborg's agentic AI and intellectual property activities, and involves shareholder approval for new share issuance that could affect existing stockholders.

FAQ

Frequently asked questions about CDT stock

How does Ticker Nerd's model rank CDT?

As at 21 Aug 2026, CDT Equity, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the CDT stock forecast for 2030?

No analyst covering CDT Equity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDT are extrapolating price history, which says nothing about the business.

What does CDT Equity, Inc. do?

Conduit Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing clinical-stage assets that address unmet medical needs.

What is the latest news on CDT?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion". CDT Equity Inc. announced it entered into a strategic transaction to increase its equity stake in Sarborg Limited, an agentic AI intelligence business, to 22.7%. The stake increase is to be funded through the issuance of pre-funded warrants for up to 12,131,770 shares of CDT common stock, subject to shareholder approval at the company's annual meeting on August 28, 2026.

Company

About CDT Equity, Inc.

Conduit Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing clinical-stage assets that address unmet medical needs. The company concentrates on therapeutic programs in autoimmune diseases and idiopathic male infertility, with research centered on conditions such as Hashimoto’s thyroiditis, uveitis, renal transplant rejection, and preterm labor. Its current pipeline includes assets such as AZD1656 and AZD5904, which are being explored for their potential applications across these treatment areas. Conduit Pharmaceuticals works at the intersection of drug development, clinical research, and asset advancement, aiming to support the progression of novel therapies through the development process. The company is headquartered in Naples, Florida.

CEO Dr. Andrew Regan · 4 employees · United States · https://www.cdtequity.com